Blurbs

Bioline RX Ltd Sponsored ADR (BLRX) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Bioline RX Ltd Sponsored ADR (BLRXResearch Report) today and set a price target of $19.00. The company’s shares opened today at $0.71.

According to TipRanks, Pantginis is an analyst with an average return of -16.9% and a 30.95% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Palatin Technologies, Actinium Pharmaceuticals, and PDS Biotechnology.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bioline RX Ltd Sponsored ADR with a $19.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

BLRX market cap is currently $51.14M and has a P/E ratio of -1.51.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi’in, Israel.

Read More on BLRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More